The University of Southampton
University of Southampton Institutional Repository

Antigenic targets for the immunotherapy of Acute Myeloid Leukaemia

Antigenic targets for the immunotherapy of Acute Myeloid Leukaemia
Antigenic targets for the immunotherapy of Acute Myeloid Leukaemia
One of the most promising approaches to preventing relapse is the stimulation of the body's own immune system to kill residual cancer cells after conventional therapy has destroyed the bulk of the tumour. In acute myeloid leukaemia (AML), the high frequency with which patients achieve first remission, and the diffuse nature of the disease throughout the periphery, makes immunotherapy particularly appealing following induction and consolidation therapy, using chemotherapy, and where possible stem cell transplantation. Immunotherapy could be used to remove residual disease, including leukaemic stem cells from the farthest recesses of the body, reducing, if not eliminating, the prospect of relapse. The identification of novel antigens that exist at disease presentation and can act as targets for immunotherapy have also proved useful in helping us to gain a better understand of the biology that belies AML. It appears that there is an additional function of leukaemia associated antigens as biomarkers of disease state and survival. Here, we discuss these findings.
Orchard, Kim
794654ab-d6cc-488a-ac11-c9217433c7a2
Khan, Ghalaza
a39a3ea0-46e5-47f0-b810-b48cff3d9dc6
Gwinn, Barbara
0c5f98e0-0cd2-430c-a0d7-178b87e3db30
Orchard, Kim
794654ab-d6cc-488a-ac11-c9217433c7a2
Khan, Ghalaza
a39a3ea0-46e5-47f0-b810-b48cff3d9dc6
Gwinn, Barbara
0c5f98e0-0cd2-430c-a0d7-178b87e3db30

Orchard, Kim, Khan, Ghalaza and Gwinn, Barbara (2019) Antigenic targets for the immunotherapy of Acute Myeloid Leukaemia. Journal of Clinical Medicine, 8 (2), [134]. (doi:10.3390/jcm8020134).

Record type: Article

Abstract

One of the most promising approaches to preventing relapse is the stimulation of the body's own immune system to kill residual cancer cells after conventional therapy has destroyed the bulk of the tumour. In acute myeloid leukaemia (AML), the high frequency with which patients achieve first remission, and the diffuse nature of the disease throughout the periphery, makes immunotherapy particularly appealing following induction and consolidation therapy, using chemotherapy, and where possible stem cell transplantation. Immunotherapy could be used to remove residual disease, including leukaemic stem cells from the farthest recesses of the body, reducing, if not eliminating, the prospect of relapse. The identification of novel antigens that exist at disease presentation and can act as targets for immunotherapy have also proved useful in helping us to gain a better understand of the biology that belies AML. It appears that there is an additional function of leukaemia associated antigens as biomarkers of disease state and survival. Here, we discuss these findings.

Text
jcm-08-00134 - Version of Record
Available under License Creative Commons Attribution.
Download (291kB)

More information

Accepted/In Press date: 20 January 2019
Published date: 23 January 2019

Identifiers

Local EPrints ID: 432440
URI: http://eprints.soton.ac.uk/id/eprint/432440
PURE UUID: beaa4cb3-9396-4441-8d56-14454515593c
ORCID for Kim Orchard: ORCID iD orcid.org/0000-0003-2276-3925

Catalogue record

Date deposited: 12 Jul 2019 16:38
Last modified: 06 Jun 2024 01:40

Export record

Altmetrics

Contributors

Author: Kim Orchard ORCID iD
Author: Ghalaza Khan
Author: Barbara Gwinn

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×